Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Oncology Inc (CTOR)

Citius Oncology Inc (CTOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,526
  • Shares Outstanding, K 83,513
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,150 K
  • EBIT $ -38 M
  • EBITDA $ -38 M
  • 60-Month Beta 2.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0600 +5.65%
on 12/05/25
1.8300 -38.80%
on 12/01/25
-0.4201 (-27.28%)
since 11/05/25
3-Month
1.0600 +5.65%
on 12/05/25
2.2500 -50.23%
on 10/16/25
-0.7601 (-40.43%)
since 09/05/25
52-Week
0.5506 +103.40%
on 03/17/25
6.1900 -81.91%
on 06/27/25
-0.5001 (-30.87%)
since 12/05/24

Most Recent Stories

More News
Citius Oncology Expands LYMPHIRâ„¢ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIRâ„¢, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

LYMPHIR now available nationwide

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology to Advance Commercial Launch of LYMPHIRâ„¢ with Verix AI Integration

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIRâ„¢ Commercial Launch

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR

CTXR : 1.1800 (-5.60%)
MCK : 808.62 (-0.68%)
CTOR : 1.1199 (+0.89%)
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

LD Micro Main Event XIX, October 19-21, 2025

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIRâ„¢

EVERSANA  to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Establishes International Access to LYMPHIRâ„¢ via Named Patient Programs in Southern Europe

Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countries

CTOR : 1.1199 (+0.89%)
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")...

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CRANFORD, N.J. , Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma")...

CTXR : 1.1800 (-5.60%)
CTOR : 1.1199 (+0.89%)
Cancer Treatment Revolution Drives $903B Market as New Therapies Gain Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Moffitt Cancer Center have uncovered a promising new therapeutic strategy that could potentially...

ONCY : 0.9921 (+1.16%)
BCT.TO : 15.80 (-7.82%)
MGNX : 1.3700 (-0.72%)
KPTI : 5.75 (-2.71%)
BCTX : 11.39 (-6.94%)
CTOR : 1.1199 (+0.89%)

Business Summary

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

See More

Key Turning Points

3rd Resistance Point 1.2499
2nd Resistance Point 1.2000
1st Resistance Point 1.1599
Last Price 1.1199
1st Support Level 1.0699
2nd Support Level 1.0200
3rd Support Level 0.9799

See More

52-Week High 6.1900
Fibonacci 61.8% 4.0357
Fibonacci 50% 3.3703
Fibonacci 38.2% 2.7049
Last Price 1.1199
52-Week Low 0.5506

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar